Safety and immunogenicity of COVAC-2, a Sepivac SWETM adjuvanted SARS-CoV-2 recombinant protein vaccine in healthy adults; a randomized controlled first-in-human dose-escalation trial.

Hamonic G, Pastural E, Arora S, et al. Vaccine. 2025;64:127748. doi:10.1016/j.vaccine.2025.127748

VFI headquarters and Geneva laboratories

Rue du Champ-Blanchod 4
1228 Plan-les-Ouates
Switzerland

VFI Lausanne laboratories

Route de la Corniche 5
1066 Epalinges
Switzerland

contact@vformulation.org
VFI on LinkedIn

© 2026 Vaccine Formulation Institute